When we evaluated other immunosuppressive factors such as the type of induction therapy, we observed a significantly higher incidence of COVID-19 among patients administered induction therapy with BR at 65%, compared to those treated with R-CHOP/R-CVP at 35% (p=0.036). This evidence concerns the gene DDIT3 and COVID-19.